Claret Capital Partners participates in €130m financing for Inventiva to support Phase 3 development

Impact · against what's priced in

Inventiva's stock is likely to see a positive bump as the €130m financing removes immediate funding risk and secures the runway for the high-stakes Q4 2026 Phase 3 readout. For BlackRock and Abivax, the news is immaterial as it represents a routine investment activity for the former and a mere mention of prior investment for the latter.

IVA+0.60

No priced-in read yet